- Adium is strategically expanding its portfolio by developing its key therapeutic areas throughout Latin America.
- By means of this agreement, Adium will acquire a range of Takeda mature assets, thus expanding its gastrointestinal line product portfolio in several Latin American countries.
- Adium will be supplied by Takeda developed products, granting patients with continuous access over the next 5 years.
MONTEVIDEO, Uruguay, 1 de septiembre de 2021
Today, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced having signed an agreement to divest a range of its product portfolio in Argentina, Colombia, Ecuador, Peru, Guatemala, Costa Rica, Panama and other Central American and Caribbean countries, in its SAM area (Southern Cone, Andean region, Mexica and CAC), a part of Takeda’s Growth & Emerging Markets Business Unit transferred to Adium Pharma S.A., subject to the respective compliance of regulatory conditions and legal requirements.
The portfolio to be acquired by Adium includes five products, mainly prescription medicines of Takeda’s gastrointestinal line, [Pantoprazole, Alevian, Dexlansoprazole, Riopan, Faktu].
Some Takeda comments in relation to Adium:
“We are confident that Adium is well-positioned to guarantee patients’ continuous access to the products subject to this transaction,” said Ricardo Marek, president of Takeda’s Growth & Emerging Markets (GEM) Business Unit (BU)”. And also, “Pursuant to this agreement, Takeda will keep on developing and supplying the products object to this contract for the next 5 years to Adium, in line with our purpose to provide better health for people and a brighter future for the world.” he added.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE: TAK) is a values- based, R&D driven global leading biopharmaceutical company, headquartered in Japan that continuously strives to offer improved health, a better future for the patient and rendering science into highly innovative drugs. Takeda’s R&D efforts are aimed at four therapeutical areas: oncology, gastroenterology (GE), neuroscience and rare diseases. The company also invests its R&D in plasma-derived therapies and vaccines. The company focuses on the development of highly innovative drugs that contribute to make the difference in people’s lives by offering new therapeutic alternatives, and improving its R&D drivers and capacities to create a robust and diversified line of products. With presence in almost 80 countries and regions, Takeda’s staff is committed to improve the quality of life of the patient working together with other allies in healthcare. For more information, visit https://www.takeda.com
Adium Pharma S.A. signed an agreement with Takeda for the acquisition of 5 pharmaceutical products, mainly prescription drugs commercialized in Argentina, Colombia, Ecuador, Perú, Guatemala, Costa Rica, Panama, as well as in other countries within Central America and the Caribbean, subject to the respective compliance of regulatory conditions and legal requirements.
Pursuant to the terms of the agreement, Takeda undertakes developing and supplying these products to Adium over the next 5 years for continuous patient access to these medicines.
Adium Group, founded in 1975, and headquartered in Uruguay, operates in 18 Latin American countries. The Company is devoted to the development, production and commercialization of pharmaceutical products, providing access to doctors and patients in Latin America to innovative and quality treatments, and with a commercial portfolio that includes proprietary branded generics and innovative pharmaceutical licensed products in the areas of oncology, rheumatology, pain, urology, women’s health, neurology, cardiology and gastroenterology.
This press release contains product information that may not be available in all countries or may be available under another brand name, for other indications, dosage or concentrations. None of the information contained shall be interpreted as an offer, promotion or publicity of the abovementioned prescription drugs.